What it's for (Indications)
- Tulobuterol is primarily indicated for the symptomatic treatment and prophylactic management of bronchial asthma and chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.
- It functions as a bronchodilator to relieve airflow obstruction and reduce the frequency and severity of bronchospasm.
- Its use is aimed at improving respiratory function and enhancing quality of life for patients experiencing reversible airway obstruction.
- The therapeutic benefit arises from its capacity to relax the smooth muscles of the airways, thereby increasing luminal diameter and facilitating easier breathing.
- It is often considered for long-term maintenance therapy rather than acute exacerbations, providing sustained bronchodilation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of tulobuterol varies significantly depending on the formulation and the patient's age and clinical condition. For the transdermal patch formulation (e.g., Bremax), common adult dosages typically involve applying a patch containing 1 mg or 2 mg of tulobuterol once daily to a clean, dry area of skin, usually on the chest, back, or upper arm. Pediatric dosages may start at 0.5 mg patches daily, adjusted based on age, weight, and clinical response, with specific guidelines for different age groups. Oral formulations or metered-dose inhalers, if available, would have distinct dosage regimens. It is imperative that patients strictly adhere to the prescribed dosage and administration instructions provided by their healthcare professional to optimize therapeutic efficacy and minimize the risk of adverse effects. Self-adjustment of dosage or frequency is strongly discouraged and can lead to serious adverse events. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with tulobuterol, consistent with other beta-2 adrenergic agonists, include fine tremor, palpitations, tachycardia, headache, nervousness, dizziness, and muscle cramps.
- Patients using transdermal patches may also experience localized skin irritation, erythema, or pruritus at the application site.
- Less frequently, but of significant clinical concern, are effects such as hypokalemia, cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia, and extrasystoles), angina, and blood pressure changes (either hypertension or hypotension).
- Paradoxical bronchospasm, though rare, can occur and necessitates immediate discontinuation of the drug and institution of alternative therapy.
- Hypersensitivity reactions, including rash, urticaria, and angioedema, have also been reported.
- Patients should be advised to report any persistent or severe side effects to their physician promptly.
Serious Warnings
- Black Box Warning: **SERIOUS WARNING: ASTHMA-RELATED DEATH (for Asthma indication)** The use of long-acting beta-2 adrenergic agonists (LABAs), such as tulobuterol, particularly when used as monotherapy for asthma, has been associated with an increased risk of asthma-related death. This risk is primarily observed in asthma patients and highlights the critical importance of using tulobuterol for asthma only as part of a combination regimen with an inhaled corticosteroid (ICS). Tulobuterol should not be used as the first-line treatment for asthma, nor should it be used to treat acute asthma exacerbations, for which a short-acting beta-2 agonist (SABA) is immediately required. The transdermal formulation, while offering sustained release, still presents this inherent class risk when not co-administered with an ICS for comprehensive asthma management. Patients using tulobuterol for asthma must be thoroughly counselled on the necessity of concurrent ICS therapy and the potential dangers of using LABAs alone or exceeding recommended dosages. Regular monitoring by a healthcare professional is essential to assess the ongoing balance of therapeutic benefits and potential risks, ensuring appropriate and safe use of this medication.
- Tulobuterol, like other beta-2 agonists, must be used with extreme caution in patients with pre-existing cardiovascular disorders, including coronary insufficiency, cardiac arrhythmias, severe hypertension, or a history of myocardial infarction, as it can cause dose-related cardiovascular effects such as increases in pulse rate, blood pressure, and prolongation of the QT interval.
- It should be used judiciously in patients with convulsive disorders, hyperthyroidism, diabetes mellitus, or unusual responsiveness to sympathomimetic amines, as these conditions may be exacerbated.
- Clinically significant hypokalemia, potentially serious, may result from beta-2 agonist administration, particularly with high doses, and may be potentiated by concomitant xanthine derivatives, steroids, or diuretics; patients should be monitored for hypokalemia.
- Paradoxical bronchospasm can occur and should prompt immediate discontinuation and evaluation of alternative therapies.
- Patients should not exceed the recommended dose due to the increased risk of adverse cardiovascular and neurological effects.
- The transdermal patch should be applied to intact, healthy skin only, and rotation of application sites is recommended to minimize irritation.
- The safety and efficacy of tulobuterol in acute asthma exacerbations have not been established; it is not intended for rescue therapy.
How it Works (Mechanism of Action)
Tulobuterol is a highly selective long-acting beta-2 adrenergic receptor agonist. Its primary mechanism of action involves the stimulation of beta-2 adrenoceptors located predominantly on the surface of bronchial smooth muscle cells. This selective activation leads to the stimulation of adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP levels result in the activation of protein kinase A, which subsequently phosphorylates various cellular proteins. This phosphorylation cascade ultimately leads to the relaxation of bronchial smooth muscle cells, causing bronchodilation and an increase in airflow within the respiratory passages. Furthermore, tulobuterol may exhibit ancillary effects, including the inhibition of the release of inflammatory mediators from mast cells and an improvement in mucociliary clearance, thereby contributing to its overall therapeutic profile in the management of reversible airway obstruction. Its sustained action provides prolonged bronchodilation, making it suitable for maintenance therapy.
Commercial Brands (Alternatives)
No other brands found for this formula.